MedTrace Logo

Immunotherapy of Cervical Cancer With V3-Cervix

NCT03550755 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-08-30

No results posted yet for this study

Summary

The goal of this trial is to evaluate the efficacy of immunotherapy for cervical cancer based on a fundamentally new approach. We will test new tableted preparation, V3-Cervix, obtained from hydrolyzed, inactivated blood and tumors of patients with cervical cancer. When administered orally, it should cause a specific anti-tumor immune response and an anti-inflammatory effect. Trial is planned to last 3 months, recruit 20 volunteers, administer daily pill of vaccine and evaluate effect on tumor size and tumor markers.

Conditions

Interventions

BIOLOGICAL

V3-Cervix

Oral tableted preparation containing hydrolyzed tumor antigens derived from peripheral blood and tumor tissue

Sponsors & Collaborators

  • Immunitor LLC

    lead INDUSTRY

Principal Investigators

  • Aldar Bourinbaiar, PhD, MD/PhD · Immunitor Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2019-11-30
Completion
2019-12-31

Countries

  • Mongolia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03550755 on ClinicalTrials.gov